Wormwood Shows Promise In Vitro But Lacks Reliable Clinical Evidence for Human Anthelmintic Use
Wormwood (Artemisia absinthium) demonstrates anthelmintic activity in laboratory studies but cannot be recommended as a reliable treatment for human helminthic infections due to insufficient clinical evidence, lack of standardized dosing, and potential neurotoxicity with prolonged use.
Evidence Quality and Limitations
The available evidence consists entirely of in vitro studies, veterinary research, and one recent failed in vivo animal trial—no human clinical trials exist to support its use as an anthelmintic in people. The most recent and relevant study 1 from 2025 actually demonstrates the critical gap between laboratory promise and clinical reality: while A. absinthium ethanolic extract showed 82% larvicidal efficacy in vitro at 200 mg/ml, it completely failed to reduce fecal egg counts in naturally infected goats at 600 mg/kg oral dosing.
Laboratory Evidence vs. Clinical Reality
In Vitro Activity
Multiple studies show wormwood extracts can kill or paralyze various helminths under laboratory conditions:
- Sheep nematodes: Ethanolic extracts achieved 90.46% fecal egg count reduction at 2.0 g/kg in sheep, comparable to albendazole 2
- Tapeworms: Demonstrated activity against Hymenolepis nana with tegumental damage and worm death 3
- Multiple trematodes: Killed Schistosoma mansoni and Fasciola hepatica at 2 mg/mL within 20-40 hours 4
- Cattle nematodes: Aqueous extracts at 10 mg/mL achieved 100% mortality of Haemonchus contortus within 6 hours 5
The Critical Failure
The 2025 goat study 1 represents the most clinically relevant evidence and shows no significant in vivo efficacy despite promising in vitro results. This disconnect likely reflects poor bioavailability, inadequate tissue concentrations, or rapid metabolism of active compounds when administered orally.
Safety Concerns
Long-term use of A. absinthium essential oil carries documented risks 6:
- Neurotoxicity with convulsions
- Sleep disturbances
- Hallucinations
- Mental disorders
These risks make empirical use particularly problematic without established therapeutic dosing and duration guidelines.
Clinical Recommendation Algorithm
For human helminthic infections:
- Use established anthelmintics (albendazole, mebendazole, ivermectin, praziquantel) as first-line therapy per standard guidelines 7
- Do not substitute wormwood for proven treatments
- Consider wormwood only in research settings with appropriate ethical oversight and informed consent
The evidence does not support clinical use of wormwood as an anthelmintic in humans. While traditional use and laboratory studies suggest potential [@6,@8@], the failure of recent in vivo testing [@2@] and absence of human trials make it an unreliable choice when effective, well-studied alternatives exist.
Key Pitfalls to Avoid
- Do not assume in vitro activity translates to clinical efficacy—the 2025 study [@2@] definitively demonstrates this disconnect
- Do not use wormwood for serious helminthic infections where treatment failure could cause significant morbidity
- Avoid prolonged use due to neurotoxicity risk [@